5月28日 - ** 减肥药开发商VERUVERU.O股价盘前上涨46%至74美分
** VERU称， (link)，在中期试验中，其实验药物enobosarm和semaglutide的组合与单独使用semaglutide相比，腹泻和恶心等胃肠道副作用更少。
** 联合用药达到了今年早些时候中期试验的主要目标 (link)
** 公司称，服用伊诺博萨姆 3 毫克和塞马鲁肽的患者脂肪减少了 99%，同时保留了瘦肌肉质量
** VERU 已要求与美国 FDA 会晤，讨论 enobosarm 的下一步计划，包括可能的后期试验
** 截至上一交易日收盘，股价累计下跌 21.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.